Is 2025 the Year of Change?
Debt reduction, progress in the pharmaceutical sector, and the prospect of growth from 2026 could encourage a turnaround!
New products and improvements in profitability could justify rising prices!
Reading Time: 1 minute
In recent years, shareholders of Bayer AG have faced challenges. The stock temporarily sank to its lowest level in two decades, primarily due to the repercussions of the acquisition of the US seed giant Monsanto in 2018. Additionally, setbacks and concerns over expiring patents have weighed heavy on the pharmaceutical sector. However, this year, management has made progress, leading investors to look more optimistically toward the future. Particularly, the announcement on November 23 that the anticoagulant Asundexian has achieved primary efficacy...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
